Hyponatremia in heart failure: Revisiting pathophysiology and therapeutic strategies

Clinical Cardiology

Volumn 33, Issue 6, 2010, Pages 322-329

  Kazory, Amir ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMIODARONE; ANGIOTENSIN; CONIVAPTAN; ELECTROLYTE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LIXIVAPTAN; LOOP DIURETIC AGENT; NITRIC OXIDE; PLACEBO; POTASSIUM; PROSTACYCLIN; SEROTONIN UPTAKE INHIBITOR; SODIUM; SODIUM CHLORIDE; SODIUM CHLORIDE COTRANSPORTER; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; HORMONE ANTAGONIST;

ADRENERGIC SYSTEM; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DETERIORATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDICATION; DRUG MECHANISM; EDEMA; ELECTROLYTE TRANSPORT; ELECTROLYTE URINE LEVEL; FLUID INTAKE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH SODIUM INTAKE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; HYPOTHYROIDISM; INTRACELLULAR TRANSPORT; KALIURESIS; KIDNEY DISTAL TUBULE; LOADING DRUG DOSE; NEPHRON; PATHOPHYSIOLOGY; PLASMA OSMOLALITY; POTASSIUM CELL LEVEL; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; REVIEW; RISK BENEFIT ANALYSIS; SHORT COURSE THERAPY; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; TREATMENT DURATION; TREATMENT PLANNING; ULTRAFILTRATION; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; URINE OSMOLALITY; WATER RETENTION; BLOOD; DOWN REGULATION; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BIOLOGICAL MARKERS; DOWN-REGULATION; HEART FAILURE; HORMONE ANTAGONISTS; HUMANS; HYPONATREMIA; PRACTICE GUIDELINES AS TOPIC; SODIUM; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME;

EID: 77953840715     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20791     Document Type: Review

References (37)

1. Gheorghiade M, Abraham WT, Albert NM, et al; OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28:980-988.
2. Rusinaru D, Buiciuc O, Leborgne L, et al. Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction. Am J Cardiol. 2009;103:405-410.
3. Yancy CW, Lopatin M, Stevenson LW, et al; ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failurewith preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47:76-84.
4. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinicalmodel. JAMA. 2003;290:2581-2587.
5. Krumholz HM, Chen YT, Bradford WD, et al. Variations in and correlates of length of stay in academic hospitals among patients with heart failure resulting from systolic dysfunction. Am J Manag Care. 1999;5:715-723.
6. Sica DA. Sodium and water retention in heart failure and diuretic therapy: basic mechanisms. Cleve Clin J Med. 2006;73(suppl 2):S2-S7.
7. Sun TW, Wang LX. Low levels of B-type natriuretic peptide predict poor clinical outcomes in patients with chronic and advanced heart failure. Med Hypotheses. 2007;68:677-679.
8. Goldsmith SR, Francis GS, Cowley AW Jr. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol. 1986;58:295-299.
9. Greenberg A. Diuretic complications. Am J Med Sci. 2000;319:10-24.
10. Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia: review and analysis of 129 reported patients. Chest. 1993;103:601-606. (Pubitemid 23070771)
11. Sica DA. Hyponatremia and heart failure - treatment considerations. Congest Heart Fail. 2006;12:55-60.
12. Sligl W, McAlister FA, Ezekowitz J, et al. Usefulness of spironolactone in a specialized heart failure clinic. Am J Cardiol. 2004;94:443-447. (Pubitemid 39119993)
13. Padilla MC, Armas-Hernández MJ, Herńandez RH, et al. Update of diuretics in the treatment of hypertension. Am J Ther. 2007;14:154-160.
14. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(11 Suppl. 1):S1-S21.
15. Ali SS, Olinger CC, Sobotka PA, et al. Loop diuretics can cause clinical natriuretic failure: a prescription for volume expansion. Congest Heart Fail. 2009;15:1-4.
16. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med. 1985;103:1-6.
17. Issa VS, Bacal F, Mangini S, et al. Hypertonic saline solution for renal failure prevention in patients with decompensated heart failure [in English and Portuguese]. Arq Bras Cardiol. 2007;89:228-232.
18. Licata G, Di Pasquale P, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003;145:459-466. (Pubitemid 36390492)
19. Arnold JM, Howlett JG, Dorian P, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol. 2007;23:21-45.
20. Parrinello G, Di Pasquale P, Licata G, et al. Long-term effects of dietary sodium intake on cytokines and neurohormonal activation in patients with recently compensated congestive heart failure. J Card Fail. 2009;15:864-873.
21. Paterna S, Di Pasquale P, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail. 2000;2:305-313.
22. Drazner MH, Palmer BF. Hypertonic saline: a novel therapy for advanced heart failure? Am Heart J. 2003;145:377-379.
23. Di Pasquale P, Sarullo FM, Paterna S. Novel strategies: challenge loop diuretics and sodium management in heart failure - part I. Congest Heart Fail. 2007;13:93-98.
24. Di Pasquale P, Sarullo FM, Paterna S. Novel strategies: challenge loop diuretics and sodium management in heart failure - part II. Congest Heart Fail. 2007;13:170-176.
25. Paterna S, Parrinello G, Cannizzaro S, et al. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure. Am J Cardiol. 2009;103:93-102.
26. Damgaard M, Norsk P, Gustafsson F, et al. Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure. Am J Physiol Regul Integr Comp Physiol. 2006;290:1294-1301.
27. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417-2423.
28. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Circulation. 2003;107:2690-2696.
29. Gheorghiade M, Gattis WA, O'Conner CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963-1971.
30. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319-1331. (Pubitemid 46513233)
31. AbrahamWT, Shamshirsaz AA, McFann K, et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006;47:1615-1621.
32. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human renal failure. Am J Physiol Renal Physiol. 2006;290:F273-F278.
33. Udelson JE, McGrew FA, Flores E, et al.Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151-2159.
34. Goldsmith SR, Elkayam U, Haught WH, et al. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail. 2008;14:641-647.
35. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction. J Am Coll Cardiol. 2008;52:1540-1545.
36. Schrier RW, Gross P, Gheorghiade M, et al; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl JMed. 2006;355:2099-2112. (Pubitemid 44749318)
37. Kazory A. Haemodialysis, not ultrafiltration, can correct hyponatraemia in heart failure. Eur J Heart Fail. 2010; 12: 208.